Apellis Pharmaceuticals
APLS
NASDAQ
IPO2017
about APLS
Apellis Pharmaceuticals specializes in developing innovative therapies for rare diseases, with a focus on complement disorders, including its lead product Coversyl, which treats conditions such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic anemia.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $20.32 | $20.32 | $19.55 | $2.6B | 2.87M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| +$1.71 | 141.86 | 5.63 | 48.67% | 47.04% | 0% |